Lumosa to initiate bridging study of analgesic injection in the US
Singapore, Dec. 5 -- Opioid misuse, addiction, and overdoses have caused significant social and economic burdens leading to the opioid crisis. LT1001 (brand name Naldebain(R)) is a prodrug of nalbuphine, an abuse-free analgesic that has been marketed worldwide for decades. Naldebain(R) is developed by Taiwan based biotech company Lumosa Therapeutics as the world's first extended-release analgesic injection for the relief of moderate/severe post-operative pain for 7 days without the side effects associated with opioids. Naldebain(R) was approved by the Taiwan Food and Drug Administration (TFDA) in March 2017.
A considerable amount of clinical data and use experience have accumulated since product launch. With confirmed safety and efficacy...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.